Cidara Therapeutics (NASDAQ:CDTX) is a biotechnology company focused on developing innovative anti-infective therapies. The company is known for its Cloudbreak® platform, which is used to create drug-Fc conjugates (DFCs) aimed at treating and preventing serious infections. Cidara's competitors include other biotech firms working on infectious disease treatments.
On September 24, 2025, Roy Buchanan from JMP Securities set a price target of $153 for CDTX. At that time, the stock was trading at $88.32, suggesting a potential increase of 73.23%. This optimistic outlook aligns with Cidara's recent advancements in its Phase 3 trial for CD388, a non-vaccine treatment for seasonal influenza.
Cidara has announced updates to its Phase 3 trial for CD388, following a positive meeting with the FDA. The trial's start has been accelerated by six months to coincide with the fall 2025 flu season. This trial is crucial, as a successful outcome could lead to a Biologics License Application (BLA) approval.
The trial will now include a broader population, such as adults over 65, individuals with high-risk co-morbidities, and those with compromised immune systems. This expansion aims to demonstrate the drug's effectiveness across diverse groups, potentially increasing its market appeal.
Currently, CDTX is priced at $88.58, reflecting a 20.53% increase, or $15.09 rise. The stock has fluctuated between $77 and $90.64 today, with the latter being its highest price in the past year. CDTX has a market cap of $2.25 billion, with a trading volume of 3,325,095 shares.
